Hypertrophic cardiomyopathy

9 trials 5 recruiting MedDRA PT
9 Registered trials
5 Recruiting
5 Unique sponsors
6 Unique IMPs
8 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
ARB 1 substance
Phase III: 3 Phase II/III: 1 Phase II: 3 Phase III/IV: 1 Phase IV: 1

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

3 trials
  • Cytokinetics Inc. Commercial
    AFICAMTEN
    2023-505797-15-00 11 countries 2024 n=175
    Ended
  • Lexicon Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-513869-39-00 13 countries 2025 n=271
    Recruiting
  • Myokardia Inc. Commercial
    MAVACAMTEN
    2022-502858-14-00 10 countries 2019 n=190
    Ended

Phase II/III

1 trial
  • Cytokinetics Inc. Commercial
    AFICAMTEN
    2024-511377-30-00 2 countries 2025 n=4
    Recruiting

Phase II

3 trials
  • Cytokinetics Inc. Commercial
    AFICAMTEN
    2023-508963-58-00 12 countries 2022 n=222
    Recruiting
  • Imbria Pharmaceuticals Inc. Commercial
    NINERAFAXSTAT TRIHYDROCHLORIDE MONOHYDRATE
    2024-515125-28-00 9 countries 2025 n=130
    Recruiting
  • Myokardia Inc. Commercial
    BMS-986435
    2023-508831-29-00 3 countries 2023 n=12
    Ended

Phase III/IV

1 trial

Phase IV

1 trial
  • Medical University Of Graz Academic
    HYDROCHLOROTHIAZIDE; VALSARTAN
    2024-520086-31-00 1 country 2026 n=40
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Cytokinetics Inc. Commercial 3 Phase II/III, Phase II, Phase III 2
Myokardia Inc. Commercial 3 Phase III/IV, Phase II, Phase III 0
Imbria Pharmaceuticals Inc. Commercial 1 Phase II 1
Lexicon Pharmaceuticals Inc. Commercial 1 Phase III 1
Medical University Of Graz Academic 1 Phase IV 1
New trials by year
2019
1
2022
1
2023
1
2024
1
2025
3
2026
1
← All indication landscapes